Edition:
United Kingdom

Cytosorbents Corp (CTSO.OQ)

CTSO.OQ on NASDAQ Stock Exchange Capital Market

11.00USD
22 Jun 2018
Change (% chg)

$0.00 (+0.00%)
Prev Close
$11.00
Open
$11.00
Day's High
$11.15
Day's Low
$10.60
Volume
2,248,219
Avg. Vol
58,796
52-wk High
$12.35
52-wk Low
$4.00

Select another date:

Mon, May 14 2018

BRIEF-Cytosorb Adds Bilirubin And Myoglobin Reduction To Eu Approved Indications For Use

* CYTOSORB® ADDS BILIRUBIN AND MYOGLOBIN REDUCTION TO EUROPEAN UNION APPROVED INDICATIONS FOR USE

BRIEF-CytoSorbents Reports Qtrly Loss Per Share $0.10

* CYTOSORBENTS REPORTS STRONG FIRST QUARTER 2018 FINANCIAL RESULTS

BRIEF-Cytosorbents Enrolls First Patient Into Pivotal U.S. Refresh 2-AKI Trial

* CYTOSORBENTS ENROLLS FIRST PATIENT INTO PIVOTAL U.S. REFRESH 2-AKI TRIAL USING CYTOSORB® DURING COMPLEX CARDIAC SURGERY Source text for Eikon: Further company coverage:

BRIEF-Cytosorbents Refinances Existing Debt With New $15 Mln Debt Facility With Bridge Bank

* CYTOSORBENTS REFINANCES EXISTING DEBT WITH NEW $15 MILLION DEBT FACILITY WITH BRIDGE BANK

BRIEF-Cytosorbents Achieves Record Revenue And Product Sales Growth In 2017

* CYTOSORBENTS ACHIEVES RECORD REVENUE AND PRODUCT SALES GROWTH IN 2017

BRIEF-Cytosorbents Expands Its Partnership With Biocon To Launch Cytosorb In Malaysia

* CYTOSORBENTS EXPANDS ITS PARTNERSHIP WITH BIOCON TO LAUNCH CYTOSORB® IN MALAYSIA

BRIEF-Cytosorbents Sees Q4 2017 Revenue About $4.6 Million

* CYTOSORBENTS PRE-ANNOUNCES PRELIMINARY FOURTH QUARTER AND FULL YEAR 2017 RESULTS AND ISSUES STOCKHOLDER LETTER

Select another date: